Clonidine, weekly-effect, skin-permeable and control-released plaster

Abstract

A release controlled percutaneous adhesive of clonidine with long curative period (7 days) is prepared from clonidine, the pressure-sensitive adhesive prepared from solvent(cyclohexane)-type acrylate-vinyl acetate copolymer, and release controlling membrane prepared from modified ethene-vinyl acetate copolymer.

Description

technical field [0001] The clonidine weekly-effect transdermal controlled-release patch of the invention relates to a medicinal transdermal therapeutic system (Transdermal Therapeutic System TTS), also known as a patch. It is used for the transdermal administration of clonidine in the treatment of hypertension, child tics, ADHD, smoking cessation, drug abstinence, migraine, analgesia, and menopausal syndrome. Background technique [0002] Clonidine is a central a2 receptor agonist, which can reduce the activity of peripheral sympathetic nerves and cause blood pressure by inhibiting the vasomotor center. Oral clonidine tablets were launched in the mid-1960s. Because of its definite curative effect, long-term use, effective protection of target organs and beneficial metabolism without side effects, long-term use is safe and reliable, so it was widely used clinically in the world in the 1970s and 1980s. Included in national pharmacopoeias and essential drug lists. Since the 1...

AI Technical Summary

Problems solved by technology

[0004] US Pat.4,559,222 has disadvantages: the use of polyisobutylene pressure-sensitive adhesive is not compatible with the skin, the area is still large, and it is easy to cause allergies and inflammation; the adhesiveness is poor, and an adhesive overlay (adhesive overlay) is required to hold it down, etc.

[0005] USPat.5175052 announced that the clonidine patch developed in Japan, although it reduces skin hypersensitivity, its curative effect only reaches 3 days

Images